PMID- 23944620
OWN - NLM
STAT- MEDLINE
DCOM- 20140310
LR  - 20191112
IS  - 0006-9248 (Print)
IS  - 0006-9248 (Linking)
VI  - 114
IP  - 8
DP  - 2013
TI  - The relationship between serum adiponectin and prognosis in patients with heart 
      failure.
PG  - 455-9
AB  - BACKGROUND: The role of adiponectin in the development of cardiac disease remains 
      less clear than in metabolic disorders. While some studies indicated that low 
      adiponectin levels were associated with cardiovascular disease, not all studies 
      have been able to show such association. Adiponectin levels may influence the 
      development of chronic heart failure, but the epidemiological data are somewhat 
      complex. Thus, the aim of this study was a survey of relationship between serum 
      Adiponectin and prognosis of patients with heart failure in Iran. METHODS AND 
      MATERIALS: In this cohort study, we evaluated 96 chronic heart failure patients. 
      Patients with systolic dysfunction that was defined as left ventricular Ejection 
      Fraction (EF) </=40 % or had a history of heart failure were included in the study. 
      At the baseline visit, all patients were examined by a physician and the 
      following information was obtained: medical history, physical examination, New 
      York Heart Association (NYHA) classification. After the first evaluation, 
      analyses of adiponectin, Pro BNP, creatinine and uric acid were performed. Then 
      the patients were followed up for a median of 12 months. RESULTS: There was a 
      significant relationship between the mean adiponectin and Pro BNP levels and the 
      ejection fraction (p=0.003 and p=0.003 respectively). Higher levels of 
      adiponectin and Pro BNP were associated with a lower ejection fraction and there 
      were no such associations between creatinine and uric acid levels. There was a 
      significant association between the functional capacity as assessed by NYHA class 
      and the mean of adiponectin and uric acid, these means that higher levels of 
      adiponectin and uric acid were associated with a higher functional class in 
      patients with CHF (p=0.03 and p=0.04 respectively). During a 12 month follow-up, 
      22 (22.9 %) patients died. In subjects who died, the baseline mean plasma 
      adiponectin and Pro BNP levels were higher compared to those who were alive at 
      the follow-up and these difference were statistically significant (19+/-7.4 
      vs.15.8+/-8 ng/ml and 9520+/-10249 vs. 3172+/-4628 ng/L p=0.000). CONCLUSION: The 
      present study demonstrated that the plasma adiponectin level increased according 
      to the severity of heart failure and also there was such relationship between Pro 
      BNP and heart failure (Tab. 3, Ref. 35).
FAU - Sokhanvar, S
AU  - Sokhanvar S
AD  - Ayatollah Mosavi Cardiology Department, Medical Science University, Zanjan, Iran.
FAU - Sheykhi, M
AU  - Sheykhi M
FAU - Mazlomzade, S
AU  - Mazlomzade S
FAU - Taran, L
AU  - Taran L
FAU - Golmohammadi, Z
AU  - Golmohammadi Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Slovakia
TA  - Bratisl Lek Listy
JT  - Bratislavske lekarske listy
JID - 0065324
RN  - 0 (Adiponectin)
SB  - IM
MH  - Adiponectin/*blood
MH  - Chronic Disease
MH  - Cohort Studies
MH  - Female
MH  - Heart Failure/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
EDAT- 2013/08/16 06:00
MHDA- 2014/03/13 06:00
CRDT- 2013/08/16 06:00
PHST- 2013/08/16 06:00 [entrez]
PHST- 2013/08/16 06:00 [pubmed]
PHST- 2014/03/13 06:00 [medline]
AID - 10.4149/bll_2013_095 [doi]
PST - ppublish
SO  - Bratisl Lek Listy. 2013;114(8):455-9. doi: 10.4149/bll_2013_095.